China Biologic's ex-CEO throws his hat in the ring

Former chief of the Nasdaq-listed biotechnlogy firm launches a $3.9 billion bid to take it private. His consortium of backers face a potential battle to bring back ownership to China.

A consortium led by former boss David Gao has filed an all-cash $3.9 billion offer for Nasdaq-listed China Biologic Products, topping an existing bid by Citic Capital Holdings  as the battle to take the plasma treatment provider private heats up anew. 

¬ Haymarket Media Limited. All rights reserved.

Sign In to Your Account To Access Exclusive FinanceAsia Content!

Please sign in to your subscription to unlock full access to our premium FA resources.

Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial - no registration fees required. Click the link to get started.

Note: This free trial is a one-time offer.

Questions?
If you have any enquiries or would like a quote for a team or company licence, please contact us at [email protected]. Our subscription team will be happy to assist you.

Share our publication on social media
Share our publication on social media